PC
PCRX.US Pacira BioSciences, Inc.
- Market cap
- USD 1.46B
- P/E
- 39.2x
- P/B
- 2.04x
- ROE
- 6.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is PCRX.US undervalued?
Graham numberPCRX.US trades 88.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pacira BioSciences, Inc. fundamental analysis
No fundamental analysis for Pacira BioSciences, Inc. yet.
Pacira BioSciences, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a …
Full company profilePacira BioSciences, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pacira BioSciences, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 276M | 287M | 337M | 421M | 430M | 542M | 667M | 675M | 701M | 726M | 729M |
| Gross Profit | 166M | 199M | 250M | 314M | 312M | 401M | 468M | 490M | 531M | 577M | 571M |
| Operating Income | -32.0M | -24.9M | 15.9M | 10.5M | 46.4M | 89.9M | 60.0M | 87.7M | -73.4M | 33.3M | 41.6M |
| EBITDA | -17.9M | -10.6M | 33.1M | 30.7M | 63.5M | 114M | 140M | 155M | 29.1M | 123M | 141M |
| Net Income | -37.9M | -42.6M | -471K | -11.0M | 146M | 42.0M | 15.9M | 42.0M | -99.6M | 7.03M | 48.1M |
| EPS | -1.02 | -1.07 | -0.01 | -0.27 | 3.33 | 0.92 | 0.34 | 0.81 | -2.15 | 0.16 | 1.18 |
| Balance Sheet | |||||||||||
| Total Assets | 391M | 628M | 689M | 831M | 1.27B | 2.08B | 1.68B | 1.57B | 1.55B | 1.26B | 1.20B |
| Total Liabilities | 172M | 349M | 368M | 476M | 655M | 1.34B | 906M | 704M | 775M | 572M | 490M |
| Shareholders' Equity | 219M | 279M | 321M | 355M | 620M | 730M | 775M | 870M | 778M | 693M | 712M |
| Cash & Short-term Investments | 173M | 311M | 383M | 292M | 522M | 656M | 289M | 279M | 485M | 238M | 296M |
| Total Debt | 109M | 276M | 291M | 352M | 541M | 1.13B | 763M | 586M | 639M | 454M | 340M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 33.5M | 17.8M | 48.9M | 70.5M | 77.0M | 126M | 145M | 155M | 189M | 152M | 178M |
| Capital Expenditure | 24.7M | 19.3M | 14.5M | 10.2M | 37.8M | 45.9M | 30.1M | 15.2M | 10.6M | 15.3M | 10.2M |
| Free Cash Flow | 8.74M | -1.48M | 34.4M | 60.4M | 39.2M | 79.9M | 115M | 139M | 179M | 137M | 167M |
| Ratios | |||||||||||
| ROE | -17.3% | -15.2% | -0.1% | -3.1% | 23.5% | 5.7% | 2.1% | 4.8% | -12.8% | 1.0% | 6.8% |
| ROA | -9.7% | -6.8% | -0.1% | -1.3% | 11.4% | 2.0% | 0.9% | 2.7% | -6.4% | 0.6% | 4.0% |
| Net Profit Margin | -13.7% | -14.9% | -0.1% | -2.6% | 33.9% | 7.8% | 2.4% | 6.2% | -14.2% | 1.0% | 6.6% |
| Debt to Equity | 0.50x | 0.99x | 0.91x | 0.99x | 0.87x | 1.55x | 0.99x | 0.67x | 0.82x | 0.66x | 0.48x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Pacira BioSciences, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 2.81M | 0.05 | 6.7% |
| 2022 | - | - | - |
| 2021 | USD 2.67M | 0.06 | 6.4% |
| 2020 | USD 1.62M | 0.04 | 1.1% |
| 2019 | USD 4.32M | 0.10 | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Pacira BioSciences, Inc.
- Insiders 3.62%
- Institutions 96.38%
- Public & others 0.00%
- Shares outstanding 39.9M
- Free float 39.4M
Top funds holding PCRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 2.40M | 6.00% | -0.23% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 1.14M | 2.86% | -4.93% | Sep 2026 |
| iShares Russell 2000 ETF | 1.00M | 2.52% | 0.00% | Oct 2026 |
| Avantis US Small Cap Value ETF | 946K | 2.37% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 808K | 2.02% | -5.87% | Sep 2026 |
| DFA U.S. Small Cap Value I | 805K | 2.02% | +41.16% | Sep 2026 |
| Impax Small Cap Institutional | 750K | 1.88% | 0.00% | Sep 2026 |
| Vanguard MStar Small Cap Value Index | 525K | 1.32% | -3.81% | Sep 2026 |
| Fidelity Small Cap Index | 434K | 1.09% | +0.31% | Aug 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 366K | 0.92% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 358K | 0.90% | 0.00% | Oct 2026 |
| iShares Russell 2000 Value ETF | 340K | 0.85% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® PhrmctlsETF | 322K | 0.81% | +2.88% | Oct 2026 |
| Applied Finance Explorer Institutional | 274K | 0.69% | +1.34% | Jul 2026 |
| Fidelity Enhanced Small Cap Core ETF | 273K | 0.68% | +0.27% | Oct 2026 |
| AZ Fd1 AZ Equity Best Value A - EUR Acc | 259K | 0.65% | 0.00% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 254K | 0.64% | 0.00% | Sep 2026 |
| DWS Small Cap Core S | 250K | 0.63% | -28.55% | Aug 2026 |
| Dimensional US Small Cap Value ETF | 235K | 0.59% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 231K | 0.58% | +1.20% | Sep 2026 |
Top institutions holding PCRX.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 6.71M | 16.80% | -0.44% | Jun 2026 |
| Doma Perpetual Capital Management LLC | 2.78M | 6.96% | 0.00% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 2.41M | 6.03% | -3.80% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 2.27M | 5.69% | +8.01% | Sep 2026 |
| State Street Corp | 2.06M | 5.16% | +7.31% | Jun 2026 |
| D. E. Shaw & Co LP | 1.95M | 4.89% | -1.63% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.69M | 4.24% | -5.18% | Jun 2026 |
| Renaissance Technologies Corp | 1.67M | 4.19% | -3.57% | Sep 2026 |
| The Goldman Sachs Group Inc | 1.53M | 3.83% | -2.73% | Jun 2026 |
| American Century Companies Inc | 1.21M | 3.04% | +19.20% | Sep 2026 |
| Geode Capital Management, LLC | 1.16M | 2.90% | +1.30% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.14M | 2.87% | -17.80% | Jun 2026 |
| LSV Asset Management | 1.07M | 2.68% | +75.93% | Sep 2026 |
| UBS Group AG | 920K | 2.31% | +63.73% | Jun 2026 |
| Impax Asset Management Group PLC | 750K | 1.88% | 0.00% | Sep 2026 |
| Two Sigma Investments LLC | 725K | 1.82% | +37.53% | Jun 2026 |
| Charles Schwab Investment Management Inc | 691K | 1.73% | -5.64% | Jun 2026 |
| Gagnon Securities LLC | 625K | 1.57% | +2.66% | Sep 2026 |
| Wellington Management Company LLP | 563K | 1.41% | +17.78% | Jun 2026 |
| Northern Trust Corp | 527K | 1.32% | +1.42% | Jun 2026 |
Pacira BioSciences, Inc. company profile
- Company name
- Pacira BioSciences, Inc.
- Ticker
- PCRX.US
- Exchange
- USA Stocks
- Listed since
- Feb 3, 2011
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 825
- Fiscal year end
- December
- Address
- 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
- Phone
- 650 242 8052
- Website
- pacira.com
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Pacira BioSciences, Inc. management
10- Mr. Frank D. LeeCEO & Director · born 1968
- Mr. Shawn M. CrossChief Financial Officer · born 1968
- Ms. Kristen Williams Esq., J.D.Chief Administrative Officer & Secretary · born 1974
- Dr. Jonathan Slonin M.D.Chief Medical Officer · born 1975
- Mr. Brendan P. TeehanChief Commercial Officer · born 1969
- Ms. Lauren Bullaro RikerPrincipal Accounting Officer & Senior VP of Finance · born 1979
- Ms. Susan MescoHead of Investor Relations
- Mr. Anthony Molloy III, Esq.Chief Legal & Compliance Officer · born 1974
- Mr. Christopher C. YoungChief Manufacturing Officer · born 1972
- Ms. Krys Corbett Esq.Chief Business Officer